Maples Group Advises Forbion on US$135 Million SPAC Combination with enGene, Inc.

Maples and Calder, the Maples Group's law firm, is pleased to have advised Forbion European Acquisition Corp. ("FEAC") on the SPAC in combination with enGene, Inc. The business combination is expected to deliver gross proceeds to enGene of approximately US$135 million. 

FEAC is a biotech-focused SPAC formed for the purpose of effecting a business combination with one or more businesses or entities. FEAC's sponsor, Forbion Growth Sponsor FEAC I B.V., is part of the Forbion group, a life sciences specialist venture fund manager with headquarters in the Netherlands.

enGene is a clinical-stage biotechnology company developing non-viral gene therapies based on its proprietary dually derivatised chitosan ("DDX") platform that are re-dosable, manufactural at scale and designed to be seamlessly integrated into community clinical practices across the globe.

A team based in the Group's London office was led by Partners Matthew Gilbert and Joanna Russell, and supported by Associate Chantel Varley-Best. The team acted as legal counsel for the SPAC. 

Commenting on the deal, Matthew Gilbert said, "We are delighted to have assisted FEAC on the funding of this SPAC and to the medical developments it will help achieve. Through the unmatched experience and capabilities of our lawyers, we continue to be selected by clients for their SPACs and business combinations across a wide range of sectors." 

Davis Polk & Wardwell London LLP, Stikeman Elliott LLP, and Loyens & Loeff N.V. acted as onshore counsel. 

The Group's unique ability to provide British Virgin Islands, Cayman Islands, Jersey, Irish and Luxembourg legal advice in addition to its capacity to provide accountancy services, independent director services as well as ancillary governance and administrative services to SPAC-related entities, makes the Group the perfect choice for international businesses considering SPAC IPOs and business combinations in Asia, the US and Europe.